Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
Retrieved on:
Tuesday, March 29, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Rett syndrome, Spinal cord, Private Securities Litigation Reform Act, Intellectual disability, Profile, Drug development, University of Texas Southwestern Medical Center, FFPM, CTA, Human, DRS, DNA, Seizure, Forward-looking statement, Patient, AAV, European Commission, GLP, Central nervous system, Survival, CNS, SEC, Toxicology, Mirare, MRCPCH, Food, Tissue, Prevalence, Quality of life, Royal commission, RNA transfection, Neurodevelopmental disorder, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Mutation, MRCP, DRG, U.S. Securities and Exchange Commission, IRSF, Development, Annual report, FDA, Health Canada, Disease, Toxicity, Gene, Pharmaceutical industry, MECP2, Rett, Research, MBBS, TSHA-102 AND MIRARE, RETT SYNDROME, TAYSHA GENE THERAPIES
Initiation of clinical development is a significant milestone for the TSHA-102 program and Rett syndrome community, said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha.
Key Points:
- Initiation of clinical development is a significant milestone for the TSHA-102 program and Rett syndrome community, said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha.
- Dr. Prasad added, There are no disease-modifying therapies to treat over 350,000 patients estimated to suffer from Rett syndrome worldwide2.
- These preclinical safety and efficacy data will be presented at the International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting taking place April 26-27, 2022 in Nashville, Tennessee.
- TSHA-102 is a self-complementary intrathecally delivered AAV9 gene replacement therapy under development for the treatment of Rett syndrome.